ArticleJMIR public health and surveillance2026
Profiles of Willingness to Use Pre-Exposure Prophylaxis Modalities and an HIV Vaccine Among Sexual and Gender Minority Individuals in Brazil, Mexico, and Peru: Cross-Sectional Online Survey.
Article in JMIR public health and surveillance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Person-centered choice and mHealth support for same-day delivery of long-acting injectable cabotegravir (ImPrEP CAB Brasil): a prospective, open-label, multicenter, quasi-experimental implementation study.Lancet regional health. Americas · 2026Article
- Using Tenofovir Diphosphate Levels to Evaluate Factors Associated With PrEP Non-Adherence and Performance of Indirect Adherence Measures in Latin America: A Prospective, Single-Arm, Open-Label, Multicentre Implementation Study (ImPrEP).Journal of the International AIDS Society · 2026Article
- Analyzing the intersection of race and income on perceived discrimination among sexual and gender diverse persons in Brazil: a nationwide cross-sectional study.BMC public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHIV incidence continues to disproportionately affect sexual and gender minority (SGM) individuals in Latin America. Pre-exposure prophylaxis (PrEP), including long-acting products, urgently need scaling up in the region. Understanding PrEP modality preferences can help design effective implementation.
objectiveThis study examined willingness to use different PrEP modalities and an HIV vaccine among SGM individuals aged 18 years or older from Brazil, Mexico, and Peru and factors associated with willingness to use 4 PrEP modalities.
methodsWe conducted a cross-sectional online survey in 2021; participants were recruited via apps (Grindr and Hornet) and social media (Facebook, Instagram, and WhatsApp). We used multivariate Poisson regression with robust variance (α=.05) to estimate prevalence ratios, identifying differences in willingness to use daily oral, event-driven oral, monthly oral, and bimonthly injectable PrEP. Models were constructed for each PrEP modality and adjusted for age, country, race, education, income, HIV risk score, HIV testing, and HIV risk perception. Variables were retained in the final adjusted models regardless of statistical significance.
resultsAmong 16,951 respondents, 10,385 (61.3%) were Brazilian, 4996 (29.5%) Mexican, and 1570 (9.3%) Peruvian. Median age was 32 (IQR 26-39) years. Among the total respondents, 12,621 (74.4%) were willing to use monthly oral PrEP; 11,153 (65.8%) daily oral PrEP; 10,212 (60.2%) bimonthly injectable PrEP; and 14,044 (82.8%) an HIV vaccine. Only 6442 (38%) were willing to use event-driven oral PrEP. In Brazil, 6082 (66.8%) were willing to use daily oral, 3162 (36.1%) event-driven, 7640 (74.9%) monthly oral, and 6450 (63.3%) injectable PrEP; in Mexico, 3242 (67.8%) daily oral, 1958 (41%) event-driven, 3728 (76.5%) monthly oral, and 2805 (57.5%) injectable PrEP; in Peru, 799 (53.1%) daily oral, 584 (39.9%) event-driven, 830 (62.5%) monthly oral, and 610 (45.9%) injectable PrEP. In multivariable models, willingness to use each of the 4 PrEP modalities was positively associated with high self-perceived HIV risk (adjusted prevalence ratios [aPRs] 1.10-1.25) and higher HIV Incidence Risk Index scores (aPRs 1.08-1.22). Having lower education was associated with lower willingness for monthly oral and bimonthly injectable PrEP (aPR=0.93, 95% CI 0.89-0.97 and aPR=0.94, 95% CI 0.90-0.99, respectively). Never having been tested for HIV and testing more than 6 months ago were associated with lower willingness for daily oral PrEP (aPR=0.89, 95% CI 0.83-0.95 and aPR=0.95, 95% CI 0.91-0.99, respectively) and bimonthly injectable PrEP (aPR=0.80, 95% CI 0.74-0.86 and aPR=0.90, 95% CI 0.86-0.94, respectively).
conclusionsOur results suggest a strong preference for long-acting formulations, including monthly oral and bimonthly injectable, among SGM individuals in Latin America. Further research is needed to address gaps in the understanding of prevention modalities. As additional PrEP modalities are included in HIV prevention programs, the development of accessible tools and community-based strategies will be essential to support informed PrEP choices and ensure equitable implementation across the region.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.